Skip to main content
SpringerLink
Log in

Lambert-Eaton Myasthenic Syndrome

  • Chapter
  • First Online:
Neuromuscular Disorders in Clinical Practice

  • 5941 Accesses

Abstract

Lambert-Eaton myasthenic syndrome is a rare presynaptic neuromuscular transmission disorder, characterized by muscle weakness, depressed tendon reflexes, posttetanic potentiation, and autonomic symptoms. This chapter covers the etiology, pathogenesis, diagnosis, treatment, and prognosis of this disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 449.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Anderson HJ, Churchill-Davidson HC, Richardson AT. Bronchial neoplasm with myasthenia; prolonged apnoea after administration of succinylcholine. Lancet. 1953;265:1291–3.

    Article  PubMed  CAS  Google Scholar 

  2. Lambert EH, Eaton LM, Rooke ED. Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol. 1956;187:612–3.

    Google Scholar 

  3. Eaton LM, Lambert EH. Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors. J Am Med Assoc. 1957;163:1117–24.

    Article  PubMed  CAS  Google Scholar 

  4. Rooke ED, Eaton LM, Lambert EH, Hodgson CH. Myasthenia and malignant intrathoracic tumor. Med Clin North Am. 1960;44:977–88.

    PubMed  CAS  Google Scholar 

  5. Lambert EH, Rooke ED. Myasthenic state and lung cancer. In: Brain WR, Norris Jr FH, editors. The remote effects of cancer on the nervous system. New York/London: Grune & Stratton; 1965. p. 67–80.

    Google Scholar 

  6. Elmqvist D, Lambert EH. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma. Mayo Clin Proc. 1968;43:689–713.

    PubMed  CAS  Google Scholar 

  7. Lambert EH, Elmqvist D. Quantal components of end-plate potentials in the myasthenic syndrome. Ann N Y Acad Sci. 1971;183:183–99.

    Article  PubMed  CAS  Google Scholar 

  8. Lennon VA, Lambert EH, Whittingham S, Fairbanks V. Autoimmunity in the Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1982;5:S21–5.

    PubMed  CAS  Google Scholar 

  9. O’Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988;111(Pt 3):577–96.

    Article  PubMed  Google Scholar 

  10. Lang B, Newsom-Davis J, Wray D, Vincent A, Murray N. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet. 1981;2:224–6.

    Article  PubMed  CAS  Google Scholar 

  11. Kim YI. Passive transfer of the Lambert-Eaton myasthenic ­syndrome: neuromuscular transmission in mice injected with plasma. Muscle Nerve. 1985;8:162–72.

    Article  PubMed  CAS  Google Scholar 

  12. Prior C, Lang B, Wray D, Newsom-Davis J. Action of Lambert-Eaton myasthenic syndrome IgG at mouse motor nerve terminals. Ann Neurol. 1985;17:587–92.

    Article  PubMed  CAS  Google Scholar 

  13. Streib EW, Rothner AD. Eaton-Lambert myasthenic syndrome: long-term treatment of three patients with prednisone. Ann Neurol. 1981;10:448–53.

    Article  PubMed  CAS  Google Scholar 

  14. Willcox N, Demaine AG, Newsom-Davis J, Welsh KI, Robb SA, Spiro SG. Increased frequency of IgG heavy chain marker Glm(2) and of HLA-B8 in Lambert-Eaton myasthenic syndrome with and without associated lung carcinoma. Hum Immunol. 1985;14:29–36.

    Article  PubMed  CAS  Google Scholar 

  15. Wirtz PW, Willcox N, van der Slik AR, et al. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J Neuroimmunol. 2005;159:230–7.

    Article  PubMed  CAS  Google Scholar 

  16. Lang B, Newsom-Davis J, Peers C, Prior C, Wray DW. The effect of myasthenic syndrome antibody on presynaptic calcium channels in the mouse. J Physiol. 1987;390:257–70.

    PubMed  CAS  Google Scholar 

  17. Smith DO, Conklin MW, Jensen PJ, Atchison WD. Decreased calcium currents in motor nerve terminals of mice with Lambert-Eaton myasthenic syndrome. J Physiol. 1995;487(Pt 1):115–23.

    PubMed  CAS  Google Scholar 

  18. Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci U S A. 1983;80:7636–40.

    Article  PubMed  CAS  Google Scholar 

  19. Nagel A, Engel AG, Lang B, Newsom-Davis J, Fukuoka T. Lambert-Eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation. Ann Neurol. 1988;24:552–8.

    Article  PubMed  CAS  Google Scholar 

  20. Sher E, Gotti C, Canal N, et al. Specificity of calcium channel autoantibodies in Lambert-Eaton myasthenic syndrome. Lancet. 1989;2:640–3.

    Article  PubMed  CAS  Google Scholar 

  21. Leys K, Lang B, Johnston I, Newsom-Davis J. Calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Ann Neurol. 1991;29:307–14.

    Article  PubMed  CAS  Google Scholar 

  22. Black III JL, Lennon VA. Identification and cloning of putative human neuronal voltage-gated calcium channel gamma-2 and gamma-3 subunits: neurologic implications. Mayo Clin Proc. 1999;74:357–61.

    Article  PubMed  CAS  Google Scholar 

  23. Olivera BM, Miljanich GP, Ramachandran J, Adams ME. Calcium channel diversity and neurotransmitter release: the omega-conotoxins and omega-agatoxins. Annu Rev Biochem. 1994;63:823–67.

    Article  PubMed  CAS  Google Scholar 

  24. Miljanich GP, Ramachandran J. Antagonists of neuronal calcium channels: structure, function, and therapeutic implications. Annu Rev Pharmacol Toxicol. 1995;35:707–34.

    Article  PubMed  CAS  Google Scholar 

  25. Greenberg DA. Calcium channels in neurological disease. Ann Neurol. 1997;42:275–82.

    Article  PubMed  CAS  Google Scholar 

  26. Uchitel OD, Protti DA, Sanchez V, Cherksey BD, Sugimori M, Llinas R. P-type voltage-dependent calcium channel mediates presynaptic calcium influx and transmitter release in mammalian synapses. Proc Natl Acad Sci U S A. 1992;89:3330–3.

    Article  PubMed  CAS  Google Scholar 

  27. Protti DA, Reisin R, Mackinley TA, Uchitel OD. Calcium channel blockers and transmitter release at the normal human neuromuscular junction. Neurology. 1996;46:1391–6.

    Article  PubMed  CAS  Google Scholar 

  28. Day NC, Wood SJ, Ince PG, et al. Differential localization of voltage-dependent calcium channel alpha1 subunits at the human and rat neuromuscular junction. J Neurosci. 1997;17:6226–35.

    PubMed  CAS  Google Scholar 

  29. Leveque C, Hoshino T, David P, et al. The synaptic vesicle protein synaptotagmin associates with calcium channels and is a putative Lambert-Eaton myasthenic syndrome antigen. Proc Natl Acad Sci U S A. 1992;89:3625–9.

    Article  PubMed  CAS  Google Scholar 

  30. Takamori M, Hamada T, Komai K, Takahashi M, Yoshida A. Synaptotagmin can cause an immune-mediated model of Lambert-Eaton myasthenic syndrome in rats. Ann Neurol. 1994;35:74–80.

    Article  PubMed  CAS  Google Scholar 

  31. Raymond C, Walker D, Bichet D, et al. Antibodies against the beta subunit of voltage-dependent calcium channels in Lambert-Eaton myasthenic syndrome. Neuroscience. 1999;90:269–77.

    Article  PubMed  CAS  Google Scholar 

  32. Titulaer MJ, Klooster R, Potman M, et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol. 2009;27:4260–7.

    Article  PubMed  CAS  Google Scholar 

  33. Sabater L, Titulaer M, Saiz A, Verschuuren J, Gure AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology. 2008;70:924–8.

    Article  PubMed  CAS  Google Scholar 

  34. Maddison P, Thorpe A, Silcocks P, Robertson JF, Chapman CJ. Autoimmunity to SOX2, clinical phenotype and survival in patients with small-cell lung cancer. Lung Cancer. 2010;70:335–9.

    Article  PubMed  Google Scholar 

  35. Pinto A, Moss F, Lang B, et al. Differential effect of Lambert-Eaton myasthenic syndrome immunoglobulin on cloned neuronal voltage-gated calcium channels. Ann N Y Acad Sci. 1998;841:687–90.

    Article  PubMed  CAS  Google Scholar 

  36. Takamori M, Iwasa K, Komai K. Antigenic sites of the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci. 1998;841:625–35.

    Article  PubMed  CAS  Google Scholar 

  37. Tischler AS, Dichter MA, Biales B. Electrical excitability of oat cell carcinoma. J Pathol. 1977;122:153–6.

    Article  PubMed  CAS  Google Scholar 

  38. Viglione MP, O’Shaughnessy TJ, Kim YI. Inhibition of calcium currents and exocytosis by Lambert-Eaton syndrome antibodies in human lung cancer cells. J Physiol. 1995;488(Pt 2):303–17.

    PubMed  CAS  Google Scholar 

  39. Meriney SD, Hulsizer SC, Lennon VA, Grinnell AD. Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma. Ann Neurol. 1996;40:739–49.

    Article  PubMed  CAS  Google Scholar 

  40. Roberts A, Perera S, Lang B, Vincent A, Newsom-Davis J. Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature. 1985;317:737–9.

    Article  PubMed  CAS  Google Scholar 

  41. Johnston I, Lang B, Leys K, Newsom-Davis J. Heterogeneity of calcium channel autoantibodies detected using a small-cell lung cancer line derived from a Lambert-Eaton myasthenic syndrome patient. Neurology. 1994;44:334–8.

    Article  PubMed  CAS  Google Scholar 

  42. Morris CS, Esiri MM, Marx A, Newsom-Davis J. Immunocyto­chemical characteristics of small cell lung carcinoma associated with the Lambert-Eaton myasthenic syndrome. Am J Pathol. 1992;140:839–45.

    PubMed  CAS  Google Scholar 

  43. Waterman SA, Lang B, Newsom-Davis J. Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse. Ann Neurol. 1997;42:147–56.

    Article  PubMed  CAS  Google Scholar 

  44. Maddison P, Pinto A, Newsom-Davis J. Endocrine function in Lambert-Eaton myasthenic syndrome. Ann Neurol. 1999;45:414–5.

    Article  PubMed  CAS  Google Scholar 

  45. Squier M, Chalk C, Hilton-Jones D, Mills KR, Newsom-Davis J. Type 2 fiber predominance in Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1991;14:625–32.

    Article  PubMed  CAS  Google Scholar 

  46. Alberca R, Gil-Peralta A, Castilla JM, Rafel E, Bautista J. Facilitating myasthenic syndrome and quadriceps myopathy. Eur Neurol. 1983;22:22–8.

    Article  PubMed  CAS  Google Scholar 

  47. Oh SJ, Dwyer DS, Bradley RJ. Overlap myasthenic syndrome: combined myasthenia gravis and Eaton-Lambert syndrome. Neurology. 1987;37:1411–4.

    Article  PubMed  CAS  Google Scholar 

  48. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10:1098–107.

    Article  PubMed  Google Scholar 

  49. Titulaer MJ, Wirtz PW, Kuks JB, et al. The Lambert-Eaton myasthenic syndrome 1988–2008: a clinical picture in 97 patients. J Neuroimmunol. 2008;201–202:153–8.

    Article  PubMed  Google Scholar 

  50. Wirtz PW, Sotodeh M, Nijnuis M, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2002;73:766–8.

    Article  PubMed  CAS  Google Scholar 

  51. Odabasi Z, Demirci M, Kim DS, et al. Postexercise facilitation of reflexes is not common in Lambert-Eaton myasthenic syndrome. Neurology. 2002;59:1085–7.

    Article  PubMed  CAS  Google Scholar 

  52. Oh SJ, Kurokawa K, Claussen GC, Ryan Jr HF. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2005;32:515–20.

    Article  PubMed  Google Scholar 

  53. Rubenstein AE, Horowitz SH, Bender AN. Cholinergic ­dysautonomia and Eaton-Lambert syndrome. Neurology. 1979;29:720–3.

    Article  PubMed  CAS  Google Scholar 

  54. Nicolle MW, Stewart DJ, Remtulla H, Chen R, Bolton CF. Lambert-Eaton myasthenic syndrome presenting with severe respiratory failure. Muscle Nerve. 1996;19:1328–33.

    Article  PubMed  CAS  Google Scholar 

  55. Chelmicka-Schorr E, Bernstein LP, Zurbrugg EB, Huttenlocher PR. Eaton-Lambert syndrome in a 9-year-old girl. Arch Neurol. 1979;36:572–4.

    Article  PubMed  CAS  Google Scholar 

  56. Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol. 2008;26:4276–81.

    Article  PubMed  Google Scholar 

  57. Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011;29:902–8.

    Article  PubMed  Google Scholar 

  58. Elrington GM, Murray NM, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry. 1991;54:764–7.

    Article  PubMed  CAS  Google Scholar 

  59. Bertol V, Gracia-Naya M, Almarcequi C, Ucles P. Overlapping myasthenic syndrome and thymoma. Neurologia. 1992;7:81–3.

    PubMed  CAS  Google Scholar 

  60. Ihara Y, Kuroda S, Otsuki S. A case of malignant thymoma associated with Eaton-Lambert-type neuromuscular transmission block and sensorimotor neuropathy. Rinsho Shinkeigaku. 1990;30:750–3.

    PubMed  CAS  Google Scholar 

  61. Lauritzen M, Smith T, Fischer-Hansen B, Sparup J, Olesen J. Eaton-Lambert syndrome and malignant thymoma. Neurology. 1980;30:634–8.

    Article  PubMed  CAS  Google Scholar 

  62. Kusunoki S, Shimpo T, Inoue K, Toyokura Y, Yoshitake T. A case of myasthenia gravis with malignant thymoma and features of Eaton-Lambert syndrome. Rinsho Shinkeigaku. 1984;24:665–9.

    PubMed  CAS  Google Scholar 

  63. Gutmann L, Phillips LH, Gutmann L. Trends in the association of Lambert-Eaton myasthenic syndrome with carcinoma. Neurology. 1992;42:848–50.

    Article  PubMed  CAS  Google Scholar 

  64. Liesveld JL, Stern A, Rosenthal SN. Myasthenic (Eaton-Lambert) syndrome in association with an indolent non-Hodgkin’s lymphoma. N Y State J Med. 1991;91:29–30.

    PubMed  CAS  Google Scholar 

  65. Morrow JD, Manian FA, Clinton ME, Stein RS. Eaton-Lambert syndrome in a patient with acute T cell lymphocytic leukemia. South Med J. 1988;81:1578–9.

    Article  PubMed  CAS  Google Scholar 

  66. Shapira Y, Cividalli G, Szabo G, Rozin R, Russell A. A myasthenic syndrome in childhood leukemia. Dev Med Child Neurol. 1974;16:668–71.

    Article  PubMed  CAS  Google Scholar 

  67. Tetu B, Ro JY, Ayala AG, Ordonez NG, Logothetis CJ, von Eschenbach AC. Small cell carcinoma of prostate associated with myasthenic (Eaton-Lambert) syndrome. Urology. 1989;33:148–52.

    Article  PubMed  CAS  Google Scholar 

  68. Clouston PD, Saper CB, Arbizu T, et al. Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome. Neurology. 1992;42:1944–50.

    Article  PubMed  CAS  Google Scholar 

  69. Agarawal SK, Birch BR, Abercrombie GF. Adenocarcinoma of the prostate and Eaton-Lambert syndrome. A previously unreported association. Scand J Urol Nephrol. 1995;29:351–3.

    Article  PubMed  CAS  Google Scholar 

  70. Sutton GP, Siemers E, Stehman FB, Ehrlich CE. Eaton-Lambert syndrome as a harbinger of recurrent small-cell carcinoma of the cervix with improvement after combination chemotherapy. Obstet Gynecol. 1988;72:516–8.

    PubMed  CAS  Google Scholar 

  71. Jacobs DH, Jamieson PW. Lambert-Eaton myasthenic syndrome associated with an ameloblastoma of the tibia. Muscle Nerve. 1993;16:986–7.

    PubMed  CAS  Google Scholar 

  72. Katirji B. Lambert-Eaton myasthenic syndrome: a harbinger to transitional cell carcinoma of the urinary bladder. J Clin Neuromuscul Dis. 2000;1:134–6.

    Article  PubMed  CAS  Google Scholar 

  73. Buckingham JM, Howard FM, Jr., Bernatz PE et al. The value of thymectomy in myasthenia gravis: a computer-assisted matched study. Ann Surg. 1976;184:453–8

    Google Scholar 

  74. Newsom-Davis J. Myasthenia gravis and related syndromes. In: Walton J, Arpati G, Ilton-Jones D, editors. Disorders of voluntary muscle. 6th ed. Edinburgh: Churchill Livingstone; 1994. p. 761–80.

    Google Scholar 

  75. Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci. 1997;147:35–42.

    Article  PubMed  CAS  Google Scholar 

  76. Lang B, Waterman S, Pinto A, et al. The role of autoantibodies in Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci. 1998;841:596–605.

    Article  PubMed  CAS  Google Scholar 

  77. Mason WP, Graus F, Lang B et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome.

    Google Scholar 

  78. Maddison P, Newsom-Davis J, Mills KR. Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 1998;65:213–7.

    Article  PubMed  CAS  Google Scholar 

  79. Hatanaka Y, Oh SJ. Ten-second exercise is superior to 30-second exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2008;37:572–5.

    Article  PubMed  Google Scholar 

  80. Tim RW, Sanders DB. Repetitive nerve stimulation studies in the Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1994;17:995–1001.

    Article  PubMed  CAS  Google Scholar 

  81. Trontelj JV, Stalberg E. Single motor end-plates in myasthenia gravis and LEMS at different firing rates. Muscle Nerve. 1991;14:226–32.

    Article  PubMed  CAS  Google Scholar 

  82. Sanders DB. The effect of firing rate on neuromuscular jitter in Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1992;15:256–8.

    PubMed  CAS  Google Scholar 

  83. McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med. 1989;321:1567–71.

    Article  PubMed  CAS  Google Scholar 

  84. Lundh H, Nilsson O, Rosen I. Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology. 1984;34:1324–30.

    Article  PubMed  CAS  Google Scholar 

  85. Kirsch GE, Narahashi T. 3,4-diaminopyridine. A potent new potassium channel blocker. Biophys J. 1978;22:507–12.

    Article  PubMed  CAS  Google Scholar 

  86. Molgo J, Lundh H, Thesleff S. Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur J Pharmacol. 1980;61:25–34.

    Article  PubMed  CAS  Google Scholar 

  87. Thomsen RH, Wilson DF. Effects of 4-aminopyridine and 3,4-­diaminopyridine on transmitter release at the neuromuscular junction. J Pharmacol Exp Ther. 1983;227:260–5.

    PubMed  CAS  Google Scholar 

  88. Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2011 Feb 16;(2):CD003279.

    Google Scholar 

  89. Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology. 2000;54:603–7.

    Article  PubMed  CAS  Google Scholar 

  90. Lindquist S, Stangel M. Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat. 2011;7:341–9.

    PubMed  CAS  Google Scholar 

  91. Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology. 2000;54:2176–8.

    Article  PubMed  CAS  Google Scholar 

  92. Oh SJ, Kim KW. Guanidine hydrochloride in the Eaton-Lambert syndrome. Electrophysiologic improvement. Neurology. 1973;23:1084–90.

    Article  Google Scholar 

  93. Chalk CH, Murray NM, Newsom-Davis J, O’Neill JH, Spiro SG. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology. 1990;40:1552–6.

    Article  PubMed  CAS  Google Scholar 

  94. Newsom-Davis J. A treatment algorithm for Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci. 1998;841:817–22.

    Article  PubMed  CAS  Google Scholar 

  95. Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert- Eaton myasthenic syndrome. Neurology. 1984;34:480–5.

    Article  PubMed  CAS  Google Scholar 

  96. Bird SJ. Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy. Neurology. 1992;42:1422–3.

    Article  PubMed  CAS  Google Scholar 

  97. Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996;47:678–83.

    Article  PubMed  CAS  Google Scholar 

  98. Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small- cell lung carcinoma. Lancet. 1999;353:117–8.

    Article  PubMed  CAS  Google Scholar 

  99. Sher E, Codignola A, Passafaro M, et al. Nicotinic receptors and calcium channels in small cell lung carcinoma. Functional role, modulation, and autoimmunity. Ann N Y Acad Sci. 1998;841:606–24.

    Article  PubMed  CAS  Google Scholar 

  100. Maddison P, Lang B, Mills K, Newsom-Davis J. Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry. 2001;70:212–7.

    Article  PubMed  CAS  Google Scholar 

  101. Titulaer MJ, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms. Ann N Y Acad Sci. 2008;1132:129–34.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Leiden University Medical Center, 9600, 2300, RC, Leiden, The Netherlands

    Jan J. G. M. Verschuuren MD, PhD

  2. Departments of Neurology, Hospital Clinic/Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Leiden University Medical Center, Barcelona, 08036, Spain

    Maarten J. Titulaer MD, PhD

  3. Department of Neurology, Queen’s Medical Centre, NG7 2UH, Nottingham, UK

    Paul Maddison MD, FRCP

Authors
  1. Jan J. G. M. Verschuuren MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maarten J. Titulaer MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Maddison MD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan J. G. M. Verschuuren MD, PhD .

Editor information

Editors and Affiliations

  1. School of Medicine Department of Neurology, University Hospitals Case Medical Center Case Western Reserve University, Cleveland, Ohio, USA

    Bashar Katirji

  2. Department of Neurology, George Washington University, Washington, District of Columbia, USA

    Henry J. Kaminski

  3. University School of Medicine Department of Neurology, Louis Stokes Cleveland VA Medical Center Case Western Reserve, Cleveland, Ohio, USA

    Robert L. Ruff

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Verschuuren, J.J.G.M., Titulaer, M.J., Maddison, P. (2014). Lambert-Eaton Myasthenic Syndrome. In: Katirji, B., Kaminski, H., Ruff, R. (eds) Neuromuscular Disorders in Clinical Practice. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6567-6_49

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-6567-6_49

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-6566-9

  • Online ISBN: 978-1-4614-6567-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation